Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate Risk Proton Radiation Clear all
Terminated Phase 3 Interventional

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04457245
View directory record Official record
Conditions
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Not applicable Interventional

Partial Breast Proton Therapy for Early Stage Breast Cancer

NCT01310530
View directory record Official record
Conditions
Breast Cancer
Interventions
Proton Beam Radiotherapy
Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

NCT00895622
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
54 Gy radiotherapy, 60 Gy radiotherapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 17, 2026, 9:58 PM EDT
Completed No phase listed Observational

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

NCT03159676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton beam
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Recruiting Phase 2 Interventional

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

NCT06088381
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
Other · Radiation · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 17, 2026, 9:58 PM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting No phase listed Observational

Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer

NCT01352429
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Proton Therapy, IMRT
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Phase 1 Interventional

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

NCT04486755
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

NCT03323463
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck
Interventions
F-FMISO PET/CT Scan, 30 Gy over 3 weeks, Cisplatin, Carboplatin, 5Fluorouracil, Proton Therapy
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Not applicable Interventional

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

NCT01617161
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton Beam Therapy, Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
13
States / cities
Jacksonville, Florida • Chicago, Illinois • College Park, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer

NCT01368055
View directory record Official record
Conditions
Prostate Cancer
Interventions
70 Gy/CGE, 72.5 Gy/CGE
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

NCT01783535
View directory record Official record
Conditions
Retinoblastoma
Interventions
vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation
Drug · Other · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

NCT01871766
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
4
States / cities
Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

NCT00602667
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

NCT03180502
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
Interventions
Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Radiation · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Recruiting Phase 2 Interventional

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

NCT05535166
View directory record Official record
Conditions
Medulloblastoma
Interventions
Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 59 Months
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
10
States / cities
Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Recruiting Phase 2 Interventional

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

NCT04900623
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
Interventions
NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
Device · Radiation · Drug
Lead sponsor
Jonathan Schoenfeld, MD, MPH
Other
Eligibility
22 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Completed Not applicable Interventional Results available

Proton Therapy for Low and Intermediate Risk Prostate Cancer

NCT00693238
View directory record Official record
Conditions
Prostate Cancer
Interventions
Low Risk Proton Radiation, Intermediate Risk Proton Radiation
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 17, 2026, 9:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272
View directory record Official record
Conditions
Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal, Dedifferentiated Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, Myxoid Pleomorphic Liposarcoma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, Malignant Tenosynovial Giant Cell Tumor of Soft Tissue, Epithelioid Hemangioendothelioma, Glomus Tumor, Inflammatory Leiomyosarcoma, Leiomyosarcoma, Ossifying Fibromyxoid Tumor, Malignant, Myoepithelioma, Synovial Sarcoma, Epithelioid Sarcoma, Perineurioma, Malignant, Clear Cell Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Granular Cell Tumor, Malignant, Melanotic Malignant Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumor, Perivascular Epithelioid Tumor, Malignant, Intimal Sarcoma, Myoepithelial Carcinoma, Undifferentiated Sarcoma, Pleomorphic Sarcoma, Undifferentiated, Round Cell Sarcoma, Undifferentiated, NTRK-Rearranged Spindle Cell Neoplasm, Phosphaturic Mesenchymal Tumor, Malignant, Round Cell Sarcoma, Well Differentiated Liposarcoma, Giant Cell Tumor of Soft Parts NOS, Low Grade Myofibroblastic Sarcoma, Dermatofibrosarcoma Protuberans, Fibrosarcomatous
Interventions
Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor
Procedure · Radiation · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Recruiting Phase 3 Interventional

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

NCT01492972
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Androgen Suppression Therapy
Radiation · Drug
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617
View directory record Official record
Conditions
Medulloblastoma
Interventions
Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine, Aerobic Training, Neurocognitive Remediation
Radiation · Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
14
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 17, 2026, 9:58 PM EDT
Terminated Early Phase 1 Interventional

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

NCT03818776
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Proton beam therapy RT
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 17, 2026, 9:58 PM EDT
Recruiting Phase 1 Interventional

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

NCT05801913
View directory record Official record
Conditions
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Leukapheresis, Lymphodepletion Therapy, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 17, 2026, 9:58 PM EDT
Terminated Not applicable Interventional

Proton Radiation Therapy in Treating Patients With Prostate Cancer

NCT01045226
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton Beam Radiation Therapy, Quality-of-Life assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 17, 2026, 9:58 PM EDT